NOCDURNA

Peak

desmopressin acetate

NDASUBLINGUALTABLET
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
2

Clinical Trials (2)

NCT04740645N/ACompleted

NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden

Started Jul 2021
1,099,551 enrolled
Adverse Drug Event
NCT00835211Phase 1Completed

Desmopressin Acetate 0.2 mg Tablets, Fasting

Started Jul 2003
48 enrolled
Healthy

Loss of Exclusivity

LOE Date
Apr 13, 2030
50 months away
Patent Expiry
Apr 13, 2030

Patent Records (4)

Patent #ExpiryTypeUse Code
10137167
May 21, 2029
U-2327
11020448
May 21, 2029
U-2327
11963995
May 21, 2029
U-2327
9974826
Apr 13, 2030
U-2327